Table 3.
Association of clinical parameters with detectable NAb against Omicron
| Patients (n) | Detectable NAb against Omicron BA.1 |
Detectable NAb against Omicron BA.2 |
|||
|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | ||
| Blood cancer patients | 80 | ||||
| Intercept | 2.80 (0.68–15.17) | 0.26 | 3.54 (0.78–23.45) | 0.21 | |
| Diagnosis (vs. acute leukemia) | |||||
| Chronic lymphocytic leukemia | 16/80 | 3.48 (0.46–2.45) | 0.30 | 7.41 (0.78–109.31) | 0.16 |
| Myelodysplastic syndrome | 3/80 | 1.21 (0.06–28.03) | 0.91 | N/A | 0.99 |
| Myeloma | 33/80 | 9.53 (0.88–131.13) | 0.13 | N/A | 0.99 |
| Lymphoma | 21/80 | 8.07 (0.88–97.32) | 0.13 | 2.49 (1.90–606.61) | 0.06 |
| Vaccine type (first and second dose) | |||||
| BNT162b2 (vs. ChAdOx1) | 35/80 | 0.46 (0.13–1.61) | 0.31 | 0.28 (0.04–1.47) | 0.23 |
| Previous COVID-19 | |||||
| SARS-CoV-2 infection before second vaccine dose | 11/80 | 6.52 (1.13–51.90) | 0.10 | 4.08 (0.52–57.99) | 0.30 |
| Anti-cancer therapya | |||||
| B cell-depleting therapy (anti-CD20 [within 12 months] or BTKi [within 28 days]) | 15/80 | 0.03 (0.003–0.14) | 0.0013 | 0.06 (0.004–0.41) | 0.04 |
| Chemo- or targeted therapy | 34/80 | 0.68 (0.10–4.17) | 0.74 | 0.55 (0.03–11.24) | 0.72 |
NAbs were binned in detected (≥40) or undetected (<40). All values were caclulated using multivariable binary logistic regression. BTKi, Bruton’s tyrosine kinase inhibitor; OR, odds ratio; CI, confidence interval; p, p-value.
a
For anti-cancer therapy, the indicated treatment was tested for patients who received the treatment vs. patients not receiving that treatment.